Merck Serono (Geneva,  Switzerland), a division of Merck KGaA, will collaborate with Flamel  Technologies (Lyon, France) to investigate the applicability of Flamel’s Medusa  technology for the extended release of a therapeutic protein in Merck Serono’s  portfolio. Under the terms of the agreement, Merck Serono will make an upfront  payment of €2 million to Flamel for investigating the therapeutic protein and  Merck Serono will fund research and development efforts to be performed at  Flamel.

News

Merck Serono (Geneva, Switzerland), a division of Merck KGaA, will collaborate with Flamel Technologies (Lyon, France) to investigate the applicability of Flamel’s Medusa technology for the extended release of a therapeutic protein in Merck Serono’s portfolio.